Showing 5271-5280 of 5644 results for "".
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- PECAA Launches the Integrated Eye Care Initiativehttps://modernod.com/news/pecaa-launches-the-integrated-eye-care-initiative/2476579/PECAA, a nationwide doctor alliance group for independent eye care professionals, has launched a new program, the “Integrated Eye Care Initiative,” which is aimed at driving informed decision making for th
- Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with Omidria Presented at ASCRShttps://modernod.com/news/clinical-study-showing-reduced-incidence-of-cystoid-macular-edema-with-omidria-presented-at-ascrs/2476575/Omeros announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the incidence of postoperative cystoid macular edema (CME), a sight-threatening complication of cataract surgery
- Drusen Characteristics Linked With AMD Risk in Fellow Eyeshttps://modernod.com/news/drusen-characteristics-linked-with-amd-risk-in-fellow-eyes/2476571/In patients with unilateral neovascular age-related macular degeneration (AMD), certain drusen features are associated with conversion to neovascular AMD in the fellow eye, according to a secondary analysis of data from a clinical trial, as re
- Cholesterol-Lowering Drugs Tied to Reduced Glaucoma Riskhttps://modernod.com/news/cholesterol-lowering-drugs-tied-to-reduced-glaucoma-risk/2476570/High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk, according to a Reuters
- InstruSafe by Summit Medical Introduces New InstruSafe XL Transport Containerhttps://modernod.com/news/instrusafe-by-summit-medical-introduces-new-instrusafe-xl-transport-container/2476565/InstruSafe by Summit Medical has introduced the new InstruSafe XL Transport Container—the first and only container of its size on the market—designed to accommodate da Vinci SP, Xi Scopes, EndoWrist and other long laparoscopic surgical instruments, according to a company news release. The XL Tra
- Pentosan Polysulfate Sodium Treatment Strongly Linked With Maculopathy and Vision Losshttps://modernod.com/news/pentosan-polysulfate-sodium-treatment-strongly-linked-with-maculopathy-and-vision-loss/2476563/Patients taking pentosan polysulfate sodium (PPS), which has been on the market for many years, appear to be at greater risk for a newly described maculopathy and vision loss, researchers report, according to Reuters. “Exposu
- Mati Therapeutics Phase 2 Nepafenac Evolute Clinical Trial Results Show Significant Postoperative Pain Reductionhttps://modernod.com/news/mati-therapeutics-phase-2-nepafenac-evolute-clinical-trial-results-show-significant-postoperative-pain-reduction/2476558/Mati Therapeutics announced that it has completed a phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute sustained ocular punctal plug drug delivery platform. The trial was a multicenter, randomized, masked evaluation of Nepafenac Evolute
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat
- Alcon Launches Advancements to the Centurion Vision System at ASCRShttps://modernod.com/news/alcon-launches-advancements-to-the-centurion-vision-system-at-ascrs/2476556/Alcon introduced new phaco technology that is part of the Centurion Vision System, including the Active Sentry Handpiece and Intrepid Hybrid Tip, at the ASCRS annual meeting. These new products, which are designed to improve safety, consistency and control during cataract surgery,